Build status - In Progress

Assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan 0.01% in ocular hypertensive or glaucomatous patients

Recruiting
18 years - 99 years
All
10 participants needed
1 Location

Brief description of study

The purpose of this study is to find out about the safety and efficacy of T4032, which is a preservative-free formulation of bimatoprost (0.01%) for the treatment of glaucoma or ocular (eye) hypertension. There will be 5 to 6 study visits and participation will last up to 12 weeks (120 days), including the screening and wash-out periods. Study visits during the treatment period (Day 1 to Day 85) will last approximately 8-10 hours. Participants will be compensated maximum $500 for completion of all study visits.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: ocular hypertension
  • Age: 18 years - 99 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 852081

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center